Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update
04 août 2022 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Appoints John Northcott as Chief Commercial Officer
01 août 2022 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
02 juin 2022 16h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 02, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations
01 juin 2022 08h00 HE
|
Arvinas Inc.
-- In honor of 20 years of targeted protein degradation, Arvinas announces $25,000 prize to recognize the efforts of an up-and-coming researcher in the field of targeted protein degradation – --...
Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development
26 mai 2022 07h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has...
Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update
05 mai 2022 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at Bank of America Securities 2022 Healthcare Conference
03 mai 2022 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Global Targeted Protein Degradation (TPD) Market Research Report 2022
11 avr. 2022 04h18 HE
|
Research and Markets
Dublin, April 11, 2022 (GLOBE NEWSWIRE) -- The "Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: An Industry Landscape Analysis of Stakeholders, Technologies,...
Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
28 févr. 2022 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference
17 févr. 2022 08h01 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...